嵌合抗原受体基因修饰的T细胞免疫治疗骨肉瘤的研究进展

摘要

骨肉瘤(OS)是一种常见骨恶性肿瘤.常规治疗方式对患者预后生存率有一定改善,但对已转移患者的作用十分有限.靶向骨肉瘤相关抗原的嵌合抗原受体基因修饰的T细胞( CAR-T)疗法是一种很有前景的治疗方式.包括靶向HER-2、IL-11Rα、ROR1和GD2等骨肉瘤相关抗原的特异性CAR-T治疗在一些基础和临床研究中均有报道,且已经表现出了对骨肉瘤良好的治疗效果.%Osteosarcoma( OS) is one common type of bone malignancy. Conventional treatments improved survival dramatically. However, conventional therapies have a few effects on patients with metastatic disease. Targeting os-teosarcoma-associated antigen, chimeric antigen receptor-modified T cell( CAR-T) therapy may promote efficacy of treatment. Specific CAR-T treatments of osteosarcoma including targeting HER-2, IL-11Rα, ROR1 and GD2 have shown a certain therapeutic effect on osteosarcoma in some basic and clinical studies.